NNC6019-0001
NN6019-4940
Phase 2 small_molecule completed
Quick answer
NNC6019-0001 for Transthyretin Amyloid Cardiomyopathy (ATTR CM) is a Phase 2 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed